期刊
THORACIC CANCER
卷 14, 期 22, 页码 2216-2221出版社
WILEY
DOI: 10.1111/1759-7714.14997
关键词
differential response; esophageal squamous cell carcinoma; immune checkpoint inhibitor; immune contexture; tumor site specific
This study describes a patient with advanced esophageal squamous cell carcinoma who exhibited a response to durvalumab plus tremelimumab for more than 6 months, except for primary resistant esophageal tumor. The esophageal tumor showed higher levels of regulatory T cells, neutrophils, and mast cells compared to the hepatic tumor. Immunohistochemistry confirmed higher expression levels of Foxp3 and myeloperoxidase (MPO) in the esophageal tumor. The heterogeneous responses to ICI combination may be related to the different immune contextures in this ESCC patient.
Immune checkpoint inhibitors (ICIs) have demonstrated efficacy in advanced esophageal squamous cell carcinoma (ESCC). Heterogeneous responses to ICIs have been reported previously. Here, we describe a patient with advanced ESCC exhibiting a response to durvalumab plus tremelimumab for more than 6 months except primary resistant esophageal tumor. The esophageal tumor had higher regulatory T cells, neutrophils, and mast cells scores estimated by NanoString platform than hepatic tumor. The immunohistochemistry study confirmed higher expression levels of Foxp3, and myeloperoxidase (MPO) in the esophageal tumor. The different immune contextures may underlie the heterogeneous responses to ICI combination in this ESCC patient.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据